Breaking News

Tweet TWEET

Pluristem Advances Its Intramuscular Hematology Program; Assembles Clinical Advisory Board of World Renowned Opinion Leaders

Pluristem Advances Its Intramuscular Hematology Program; Assembles Clinical
Advisory Board of World Renowned Opinion Leaders

HAIFA, Israel, Dec. 4, 2012 (GLOBE NEWSWIRE) -- Pluristem Therapeutics, Inc.
(Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell
therapies, announced today that the Company has established its Clinical
Advisory Board (CAB) in hematology. The CAB includes prestigious physicians,
researchers and leaders from the field of hematology from around the world. In
a recent meeting between the advisory board and the company, hematological
indications for Pluristem's PLacental eXpanded (PLX) cells were evaluated.
Pluristem's goal is to commercialize PLX cell products for pressing
hematological indications via intramuscularly (IM) injections.

"I am pleased that these knowledgeable and renowned leaders are confident
that, based on data presented, PLX cells could have therapeutic potential in
several hematological indications," said Zami Aberman, Chairman and CEO of
Pluristem. "We believe that the IM administration of PLX cells may become a
"game changer" in treating the diseased or injured bone marrow of patients.
Following the meeting with the CAB, we have established a process to determine
which hematological indications we should advance into clinical trials."

Pluristem is pleased to include the following members into the hematology CAB:

  *Fred Appelbaum MD, PhD - President of Seattle Cancer Care Alliance, Senior
    Vice President and Director of Clinical Research Division of Fred
    Hutchinson Cancer Research Center, Head of Division of Medical Oncology of
    University of Washington; Seattle, WA
    
  *Richard Champlin MD - Chair, Department of Blood and Marrow
    Transplantation at the University of Texas, MD Anderson Cancer Center;
    Houston, TX. He is Past President of Center for International Blood and
    Marrow Transplant Research and was the founding President of the American
    Society for Blood and Marrow Transplantation
    
  *Edwin M. Horwitz, MD, PhD - Director of Cell Therapy in the Division of
    Oncology / Blood & Marrow Transplantation at Children's Hospital of
    Philadelphia; Philadelphia, PA
    
  *Hillard M. Lazarus, MD, FACP - Professor of Medicine, Case Western Reserve
    University, Cleveland, OH, The George & Edith Richman Professor and
    Distinguished Scientist in Cancer Research, Director, Novel Cell Therapy,
    University Hospitals Case Medical Center (UHCMC) Medical Director, Cell
    Therapy Integrated Services (CTIS), National Center for Regenerative
    Medicine (NCRM), UHCMC
    
  *Reuven Or MD - Director of the Bone Marrow Transplantation and Cancer
    Immunology, Hadassah Medical Center; Ein Kerem, Israel
    
  *Jacob M Rowe - Chief, Department of Hematology, Shaare Zedek Medical
    Center, Jerusalem. Emeritus Professor of Hemato-oncology, Bruce Rappaport
    Faculty of Medicine, Israel Institute of Technology, Haifa, Israel.
    Adjunct Professor of Medicine, Northwestern University, Chicago, Illinois,
    USA

Following positive data in the use of PLX cells in preclinical and clinical
studies in stimulating the production of blood cells in diseased or injured
bone marrow, the company accelerated the development of these cells for use in
hematology. By assembling internationally acclaimed thought leaders in the
field of hematology, the company stands ready to pursue indications in this
area.

About Pluristem Therapeutics

Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR) is a leading developer
of placenta-based cell therapies. The Company's patented PLX (PLacental
eXpanded) cells are a drug delivery platform that releases a cocktail of
therapeutic proteins in response to a host of local and systemic inflammatory
and ischemic diseases. PLX cells are grown using the company's proprietary 3D
micro-environmental technology and are an "off-the-shelf" product that
requires no tissue matching prior to administration. Pluristem is focusing on
the development of PLX cells administered locally to potentially treat
systemic diseases and potentially obviating the need to use the intravenous
route.

Pluristem has a strong patent and patent applications portfolio, company-owned
GMP certified manufacturing and research facilities, strategic relationships
with major research institutions and a seasoned management team. For more
information visit www.pluristem.com, the content of which is not part of this
press release.

The Pluristem Therapeutics Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=6882

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of
the "safe harbor" provisions of the Private Securities Litigation Reform Act
of 1995 and federal securities laws. For example, when we say that our goal is
to commercialize PLX cell products for pressing hematological indications via
intramuscularly (IM) injections, when we discuss that PLX cells could have
therapeutic potential in several hematological indications and our readiness
to pursue such indications, or when we discuss our belief that the IM
administration of PLX cells may become a "game changer" in treating the
diseased or injured bone marrow of patients , we are using forward-looking
statements. These forward-looking statements are based on the current
expectations of the management of Pluristem only, and are subject to a number
of factors and uncertainties that could cause actual results to differ
materially from those described in the forward-looking statements. The
following factors, among others, could cause actual results to differ
materially from those described in the forward-looking statements: changes in
technology and market requirements; we may encounter delays or obstacles in
launching and/or successfully completing our clinical trials; our products may
not be approved by regulatory agencies, our technology may not be validated as
we progress further and our methods may not be accepted by the scientific
community; we may be unable to retain or attract key employees whose knowledge
is essential to the development of our products; unforeseen scientific
difficulties may develop with our process; our products may wind up being more
expensive than we anticipate; results in the laboratory may not translate to
equally good results in real surgical settings; results of preclinical studies
may not correlate with the results of human clinical trials; our patents may
not be sufficient; our products may harm recipients; changes in legislation;
inability to timely develop and introduce new technologies, products and
applications; loss of market share and pressure on pricing resulting from
competition, which could cause the actual results or performance of Pluristem
to differ materially from those contemplated in such forward-looking
statements. Except as otherwise required by law, Pluristem undertakes no
obligation to publicly release any revisions to these forward-looking
statements to reflect events or circumstances after the date hereof or to
reflect the occurrence of unanticipated events. For a more detailed
description of the risks and uncertainties affecting Pluristem, reference is
made to Pluristem's reports filed from time to time with the Securities and
Exchange Commission.

CONTACT: Pluristem Therapeutics Inc.:
        
         William Prather R.Ph., M.D. Sr. VP Corporate Development
         1-303-883-4954
         William.PratherMD@pluristem.com
        
         Daya Lettvin
         Investor & Media Relations Director
         +972-54-674-5580
         daya@pluristem.com

Pluristem Therapeutics Inc. Logo